Intellia Therapeutics CEO John Leonard has, for the final couple years, discovered himself caught in a monetary Groundhog Day. Repeatedly, the corporate has introduced optimistic information from its gene modifying trials, solely to observe the inventory slide.
The inventory market is notoriously fickle, notably round buzzy gene-editing firms. But the selloffs pointed to actual questions across the biotech’s applications: Clearly, its CRISPR-based medicine had been efficient. However had been they any simpler than different medicine that use older, much less sci-fi applied sciences?
Intellia tried to allay a few of these issues on Saturday with new year-long information from the 36 sufferers handled in an early trial of its CRISPR drug for ATTR cardiomyopathy.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
